In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation  After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk Single ascending dose (S ...

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. ("Marti†or the "Company†) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of December 31, 2025, Marti's ride-hailing service has reached 3.38 million riders and 450 thousand registered drivers, exceeding the December 31, 2025 targets of 3.30 million riders and 450 thousand registered drivers. Marti's number of ride- hailing riders grew 34% from August 12, 2025 to December 31, 2025. The number of registered d. ...

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. ("Marti†or the "Company†) (NYSE American: MRT), Türkiye's leading mobility super app, today announced that it expects to exceed guidance for 2025. In addition, the Company has initiated strong guidance for 2026. For 2026, Marti expects $70 million of revenue, representing over 2x year-over-year revenue growth, and to achieve positive adjusted EBITDA. | 2025 Guidance | 2026 Guidance | Change | | | --- | --- | --- | --- | | Revenue | $34.0 million | $70.0 ...

Core Insights - Monte Rosa Therapeutics is advancing MRT-8102, a first-in-class NEK7-directed molecular glue degrader (MGD) aimed at treating cardiovascular and cardiometabolic diseases driven by the NLRP3 inflammasome [1][2][4] Group 1: MRT-8102 Overview - MRT-8102 is designed to selectively degrade NEK7, which is essential for NLRP3 inflammasome assembly and activation, thereby inhibiting inflammatory cytokine release [4][5] - The investigational drug has shown potent inhibition of pyroptotic cell death and cytokine release in preclinical studies, indicating its potential effectiveness in treating conditions like pericarditis and atherosclerosis [2][4] Group 2: Clinical Development - A Phase 1 study of MRT-8102 is currently enrolling participants, with initial data expected to be presented in the first half of 2026 [1][2] - The drug has demonstrated a significant safety margin in toxicology studies, with over a 200-fold exposure margin compared to projected human efficacious doses [5] Group 3: Scientific Presentation - Preclinical data on MRT-8102 will be presented at the American Heart Association's Scientific Sessions 2025, highlighting its unique mechanism of action in modulating the NLRP3 inflammasome [1][2] Group 4: Company Background - Monte Rosa Therapeutics focuses on developing highly selective MGD medicines for serious diseases, utilizing a proprietary discovery engine that combines AI-guided chemistry and structural biology [6]

Core Insights - Marti Technologies, Inc. has launched its ride-hailing service in 10 additional cities across Türkiye, marking the company's largest single wave of expansion to date [1] - With this rollout, Marti's ride-hailing operations now cover a total of 20 markets across Türkiye [1] - This expansion follows a successful summer rollout into six major metropolitan areas, including Bursa [1]

Core Insights - Marti Technologies, Inc. has announced the expansion of its service offerings to include same-hour package deliveries, enhancing its position as Türkiye's leading mobility super app [1] - The new package delivery services will utilize the existing network of 382,000 registered motorcycle and car drivers, along with over 6.4 million unique users of its super app [1]

Core Viewpoint - Marti Technologies, Inc. has announced an extension of its share repurchase program, allowing the company to buy back up to $2.5 million of its Class A ordinary shares until April 9, 2026 [1]. Summary by Relevant Sections - **Share Repurchase Program** - The Board of Directors has authorized a six-month extension to the existing share repurchase program [1]. - The total amount allocated for the repurchase is $2.5 million [1]. - The program was originally initiated on January [1].

Core Insights - Marti Technologies, Inc. has been added to the S&P Global Broad Market Index, effective September 22, 2025, marking a significant milestone for the company [1][2]. Company Overview - Founded in 2018, Marti is Türkiye's leading mobility app, providing a range of transportation services including ride-hailing, e-mopeds, e-bikes, and e-scooters, all supported by proprietary software and IoT infrastructure [3]. Business Growth - The company has experienced rapid growth in its ride-hailing service, achieving 2.28 million unique riders, a 107% year-over-year increase, and 327 thousand registered drivers, a 92% increase [6]. - As of August 12, 2025, Marti's ride-hailing service reached 2.52 million riders and 357 thousand registered drivers, surpassing its targets for September 30, 2025, by achieving these numbers a month and a half early [9]. Market Position - Marti's inclusion in the S&P Global BMI will enhance its visibility among index-tracking and new investors, aiding in the expansion of its ride-hailing operations to capture long-term mobility market opportunities in Türkiye [2]. - The S&P Global BMI encompasses over 14,000 companies across developed and emerging markets, employing a transparent methodology [2].

Core Insights - Marti Technologies, Inc. (MRT) is a prominent player in Türkiye's mobility sector, particularly known for its comprehensive ride-hailing super app [1] - The company reported a significant increase in ride-hailing riders, reaching 2.28 million, which is a 107% rise year-over-year [1][5] - MRT's earnings report showed an EPS of -0.31, aligning with estimates, while revenue was $14.33 million, slightly below the expected $14.43 million [2][5] Financial Metrics - MRT has a price-to-sales ratio of 9.62, indicating a high market valuation relative to its sales [3][5] - The enterprise value to sales ratio is 13.37, suggesting a substantial valuation when factoring in debt and cash [3] - The company has a negative price-to-earnings ratio of -1.87 and an earnings yield of -53.39%, reflecting ongoing financial difficulties [3] - MRT's enterprise value to operating cash flow ratio is -9.95, highlighting cash flow challenges [4] - The debt-to-equity ratio of -1.22 indicates that MRT has more liabilities than equity [4] - Despite financial hurdles, MRT maintains a current ratio of 1.69, suggesting adequate current assets to cover short-term liabilities [4]

Financial Performance - Revenue for the first half of 2025 was $14,326,434, a 70.5% increase compared to $8,408,711 in the same period of 2024[4] - Net loss for the first half of 2025 was $19,278,511, compared to a net loss of $21,868,930 in the first half of 2024, representing a 11.8% improvement[4] - The Group reported net revenue of $14,326,434 for the six months ended June 30, 2025, representing a 70.5% increase from $8,408,711 in the same period of 2024[31] - The Group incurred a segment loss before income tax expense of $19,278,511 for the six months ended June 30, 2025, compared to a loss of $21,868,930 for the same period in 2024, indicating an improvement of 11.9%[31] - The basic and diluted loss per share for 2025 was $(0.26), an improvement from $(0.38) in 2024[66] Assets and Liabilities - Total assets decreased to $17,215,539 as of June 30, 2025, down from $20,378,649 at the end of 2024, a decline of 15.5%[3] - Total liabilities increased to $90,378,192 as of June 30, 2025, compared to $81,819,560 at the end of 2024, an increase of 10.5%[3] - Cash and cash equivalents at the end of the period were $4,208,116, down from $5,148,857 at the beginning of the period, a decrease of 18.3%[9] - The Group's accumulated losses reached $158,765,689 as of June 30, 2025, with net losses of $19,278,511 for the same period[18] - Total financial liabilities increased to $82,989,141 as of June 30, 2025, compared to $74,675,170 at the end of 2024, reflecting an increase of 11.1%[47] Operating Expenses - Operating expenses for the first half of 2025 totaled $26,864,588, slightly higher than $26,627,436 in the same period of 2024[4] - Cost of revenues decreased to $7,367,528 in the first half of 2025, down 25.5% from $9,886,487 in the same period of 2024[38] - General and administrative expenses rose to $12,184,292 in 2025, an increase of 34.9% compared to $9,053,084 in 2024[38] - Selling and marketing expenses dropped significantly to $3,067,288, down 52.5% from $6,461,905 in 2024[38] - Research and development expenses increased to $1,111,242, up 81.9% from $611,317 in 2024[38] Shareholder Information - The weighted average shares used to compute basic and diluted net loss per share increased to 73,957,742 in the first half of 2025 from 57,818,937 in the same period of 2024[4] - The weighted-average shares outstanding increased from 57,818,937 in 2024 to 73,957,742 in 2025[66] - The company had 2,394,840 stock options outstanding as of June 30, 2025, which were excluded from the computation of diluted net loss per share due to being anti-dilutive[69] Legal Matters - The company is currently involved in a legal dispute regarding its ride-hailing services, with a court ruling in favor of the plaintiff on July 19, 2024[61] - The court's decision to block access to the ride-hailing app was lifted on June 20, 2023, after the company appealed[60] - The case has been postponed to September 26, 2025, for the expert committee to submit its report[63] - Individual taxi drivers may file separate lawsuits against the company for compensation due to actual losses from the ride-hailing service[64] Future Outlook - The Group's management has assessed that adequate resources and liquidity are available to meet cash flow requirements for the next twelve months[21] - The Group launched a unified subscription-based platform on October 1, 2024, integrating ride-hailing and electric vehicle services[28] - The Group operates as a single reportable segment, reflecting a strategic alignment in its internal organization and reporting structure[27] Financial Instruments - Proceeds from the issuance of convertible notes amounted to $8,375,750 in the first half of 2025, compared to $7,500,000 in the same period of 2024[9] - The Group has entered into a Note Subscription Agreement for up to $23,000,000 in 12.50% Convertible Senior Secured Notes due 2029, with $4,000,000 subscribed as of June 30, 2025[20] - The company has convertible notes with a total amount of $82,098,192 as of June 30, 2025, which includes $79,300,049 in-the-money at an exercise price of $1.65[48] Subsequent Events - The company has evaluated subsequent events and determined that there are no events requiring disclosure in the interim condensed consolidated financial statements[70]